The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
P-glycoprotein Inhibition for Optimal Drug Delivery
Open accessAbstract
P-glycoprotein (P-gp), an efflux membrane transporter, is widely distributed throughout the body and is responsible for limiting cellular uptake and the distribution of xenobiotics and toxic substances. Hundreds of structurally diverse therapeutic agents are substrates to it and it impedes the absorption, permeability, and retention of the drugs, extruding them out of the cells. It is overexpressed in cancer cells and accountable for obstructing cell internalization of chemotherapeutic agents and for developing transporter mediated resistance by cancer cells during anti-tumor treatments. As it jeopardizes the success of drug delivery and cancer targeting, strategies are being developed to overcome P-gp mediated drug transport. This concise review represents a brief discussion on P-gp mediated drug transport and how it hinders the success of various therapies. Its main focus is on various strategies used to tackle this curb in the field of drug delivery and targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Phosphatidylcholine translocase: A physiological role for the mdr2 gene
Ruetz, S. (1994) · Cell · doi:10.1016/0092-8674(94)90446-4 · Cited by 599
Mechanisms of bacterial biocide and antibiotic resistance: ANTIBIOTIC AND BIOCIDE RESISTANCE
Poole, K. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.8.x · Cited by 513
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., & Gabizón, A. (2000) · PubMed · Cited by 468
Lomovskaya, O., & Bostian, K. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.008 · Cited by 460
Evolution and spread of antibiotic resistance
Normark, B. H., & Normark, S. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01026.x · Cited by 440
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
Varma, M. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00158-0 · Cited by 418
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
Multidrug Resistance Reversal Agents
Robert, J., & Jarry, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030183a · Cited by 292
Emilienne Soma, C., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281
Renau, T. E., Léger, R., Flamme, E. M., Sangalang, J., She, M. W., Yen, R., Gannon, C. L., Griffith, D., Chamberland, S., Lomovskaya, O., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9904598 · Cited by 260
BEAULIEU, É., DEMEULE, M., GHITESCU, L., & BÉLIVEAU, R. (1997) · Biochemical Journal · doi:10.1042/bj3260539 · Cited by 253
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Kemper, E. M., van Zandbergen, A. E., Cleypool, C. G. J., Mos, H. A., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2003) · PubMed · Cited by 243
Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Bansal, T., Jaggi, M., Khar, R., & Talegaonkar, S. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3rc77 · Cited by 238
Batrakova, E., Dorodnych, T., Klinskii, E., Kliushnenkova, E., Shemchukova, O., Goncharova, O., Arjakov, S., Alakhov, V., & Kabanov, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.587 · Cited by 228
Overview of P-glycoprotein inhibitors: a rational outlook
Srivalli, K. M. R., & Lakshmi, P. K. (2012) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502012000300002 · Cited by 225
P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design
Raub, T. J. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0500871 · Cited by 221
A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus
Gibbons, S. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg044 · Cited by 213
van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A., Borst, P., Nooijen, W., & Beijnen, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.530 · Cited by 202
Natural and Synthetic Polymers as Inhibitors of Drug Efflux Pumps
Werle, M. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9347-8 · Cited by 197
Effect of quercetin on hoechst 33342 transport by purified and reconstituted p-glycoprotein
Shapiro, A. B., & Ling, V. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00826-x · Cited by 194
Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J., Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R., Guns, E. S. T., et al. (2000) · PubMed · Cited by 190
Waltzing transporters and 'the dance macabre' between humans and bacteria
Lomovskaya, O., Zgurskaya, H. I., Totrov, M., & Watkins, W. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2200 · Cited by 183
Pluronic P85 Enhances the Delivery of Digoxin to the Brain: In Vitro and in Vivo Studies
Batrakova, E. V., Miller, D. W., Li, S., Alakhov, V. Y., Kabanov, A. V., & Elmquist, W. F. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38781-6 · Cited by 182
The Role of Passive Transbilayer Drug Movement in Multidrug Resistance and Its Modulation
Eytan, G. D., Regev, R., Oren, G., & Assaraf, Y. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12897 · Cited by 182
Drori, S., Eytan, G. D., & Assaraf, Y. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.1020m.x · Cited by 179
Kuppens, I. E. L. M., Witteveen, E. O., Jewell, R. C., Radema, S. A., Paul, E. M., Mangum, S. G., Beijnen, J. H., Voest, E. E., & Schellens, J. H. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2414 · Cited by 177
Mechanisms of resistance to antibiotics
Wright, G. D. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.08.004 · Cited by 175
Bambeke, F., Pages, J.-M., & Lee, V. (2006) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489106777452692 · Cited by 171
Huet, A. A., Raygada, J. L., Mendiratta, K., Seo, S. M., & Kaatz, G. W. (2008) · Microbiology · doi:10.1099/mic.0.2008/021188-0 · Cited by 163
Malingré, M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., Jewell, R. C., Paul, E. M., Huinink, W. W. T. B., & Schellens, J. H. M. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1543 · Cited by 154
The effect of verapamil on the pharmacokinetics of adriamycin
Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J., & Kaye, S. B. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00273394 · Cited by 145
Woo, J. S., Lee, C. H., Shim, C. K., & Hwang, S. (2003) · Pharmaceutical Research · doi:10.1023/a:1022286422439 · Cited by 133
Döppenschmitt, S., Spahn-Langguth, H., Regårdh, C. G., & Langguth, P. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980378j · Cited by 127
Melaine, N., Liénard, M.-O., Dorval, I., Goascogne, C. L., Lejeune, H., & Jégou, B. (2002) · Biology of Reproduction · doi:10.1095/biolreprod.102.003558 · Cited by 124
Doxorubicin-peptide conjugates overcome multidrug resistance
Mazel, M., Clair, P., Rousselle, C., Vidal, P., Scherrmann, J., Mathieu-Mahul, D., & Temsamani, J. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200102000-00003 · Cited by 122
Tidefelt, U., Liliemark, J. O., Gruber, A., Liliemark, E., Sundman‐Engberg, B., Juliusson, G., Stenke, L., Elmhorn‐Rosenborg, A., Möllgård, L., Lehman, S., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1837 · Cited by 100
Kwak, J., Lee, S. H., Lee, G. S., Kim, M. S., Ahn, Y., Lee, J. H., Kim, S. W., Kim, K. H., & Lee, M. G. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.008 · Cited by 81
Evaluation of In Vivo P-Glycoprotein Phenotyping Probes: A Need for Validation
JOSEPH, D. R., Tsunoda, S. M., Bertino, J., Trivedi, M. V., Beale, K. K., & Nafziger, A. N. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318000-000000000-00000 · Cited by 69
Influence of P-Glycoprotein Inhibitors on Accumulationof Macrolides in J774 MurineMacrophages
Seral, C., Michot, J.-M., Chanteux, H., Mingeot‐Leclercq, M., Tulkens, P. M., & Françoise Van Bambeke, A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1047-1051.2003 · Cited by 67
Leitner, I., Nemeth, J., Feurstein, T., Abrahim, A., Matzneller, P., Lagler, H., Erker, T., Langer, O., & Zeitlinger, M. A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq526 · Cited by 54
Matsuo, H., Wakasugi, M., Takanaga, H., Ohtani, H., Naito, M., TSURUO, T., & Sawada, Y. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00460-6 · Cited by 48
Banerjee, S. K., Jagannath, C., Hunter, R. L., & Dasgupta, A. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00786-4 · Cited by 44
Fortuna, A. C., Alves, G., & Falcão, A. C. (2011) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.s2-001 · Cited by 40
Cited by
Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins
Yang, N. J., & Hinner, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2272-7_3 · Cited by 826
Superparamagnetic Iron Oxide Nanoparticles—Current and Prospective Medical Applications
Dulińska-Litewka, J., Łazarczyk, A., Hałubiec, P., Szafrański, O., Karnas, K., & Karewicz, A. (2019) · Materials · doi:10.3390/ma12040617 · Cited by 580
Materials for oral delivery of proteins and peptides
Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 520
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., & Tuo, D. (2018) · Cells · doi:10.3390/cells7040024 · Cited by 298
Metadata
- Authors
- Amin, M. L.
- Venue
- Drug Target Insights
- Publisher
- Aboutscience Srl
- Published
- 2013-01
- Volume
- 7
- Pages
- DTI.S12519
- ISSN
- 1177-3928 (ISSN-L)
- OpenAlex
- W2032222317
- Cited by
- 624
- References
- 51
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.